KMID : 0624620110440040232
|
|
BMB Reports 2011 Volume.44 No. 4 p.232 ~ p.237
|
|
Current progress on development of respiratory syncytial virus vaccine
|
|
Chang Jun
|
|
Abstract
|
|
|
Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to certain vaccine candidates leading to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. A wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, our great efforts will lead us to reach the goal of attaining safe and effective RSV vaccines in the near future.
|
|
KEYWORD
|
|
Pathogenesis, Protection, Respiratory syncytial virus, Vaccine, Vaccine strategy
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|